Frontage is a CRO providing integrated, scientifically-driven research, analytical and product development services throughout the drug discovery and development process to enable biopharmaceutical companies to achieve their drug development goals.
We offer our clients comprehensive services in analytical testing and formulation development, drug metabolism and pharmacokinetics (DMPK), bioanalysis, preclinical safety and toxicology and early phase clinical studies. We have enabled many innovator, generic and consumer health companies of all sizes to file IND, NDA, ANDA, BLA and 505(b)(2) submissions in global markets allowing for successful development of important therapies and products for patients.
We successfully assist clients to advance hundreds of molecules through development to commercial launch in global markets. We are committed to providing rigorous scientific expertise to ensure the highest quality and compliance.

Frontage offers comprehensive expertise across a wide spectrum of projects from stand-alone exploratory toxicology to fully integrated IND programs, including general toxicology, safety pharmacology, and genetic toxicology.

Frontage’s newest facility in Hayward, CA started operations in 2022. With over 19,000 in. square footage, it supports bioanalytical and biologics projects. The Biologics Services Department provides exploratory and GLP-compliant Ligand Binding Assay (LBA) services to biotech and pharmaceutical industries, supporting pharmacokinetics (PK), immunogenicity (ADA), and biomarker analysis for protein therapeutics. The Bioanalytical Services Department provides R&D and GLP-compliant, quantitative mass spectrometry services to biotech and pharmaceutical industries, supporting all preclinical and clinical PK / TK / DDI / BA / BE, protein binding, and biomarker studies.